The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology.
Fotios Loupakis
No relevant relationships to disclose
Dongyun Yang
No relevant relationships to disclose
Wu Zhang
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Takeru Wakatsuki
No relevant relationships to disclose
Lisa Salvatore
No relevant relationships to disclose
Carlotta Antoniotti
No relevant relationships to disclose
Giuseppe Aprile
No relevant relationships to disclose
Marta Schirripa
No relevant relationships to disclose
Vincenzo Ricci
No relevant relationships to disclose
Sara Lucchesi
No relevant relationships to disclose
Gianluca Masi
No relevant relationships to disclose
Martin Karl Herbert Maus
No relevant relationships to disclose
Sara Lonardi
No relevant relationships to disclose
Yan Ning
No relevant relationships to disclose
Rita El-Khoueiry
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose
Heinz-Josef Lenz
Consultant or Advisory Role - Roche/Genentech